Psilocybin

PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta

Retrieved on: 
Tuesday, April 2, 2024
Psilocybin, FAQ, Therapy, LSD, COVID-19, Patient, PAT, DMT, Private sector, Doctor of Philosophy, Insurance, Psychology, MDMA, FDA, Nursing

OTTAWA, April 02, 2024 (GLOBE NEWSWIRE) -- PsyCan, the not-for-profit trade association for the legal Canadian psychedelic medicine industry, welcomes the expansion of insurance coverage for psychedelic-assisted therapy (PaT) led by the Alberta Blue Cross.

Key Points: 
  • OTTAWA, April 02, 2024 (GLOBE NEWSWIRE) -- PsyCan, the not-for-profit trade association for the legal Canadian psychedelic medicine industry, welcomes the expansion of insurance coverage for psychedelic-assisted therapy (PaT) led by the Alberta Blue Cross.
  • “We welcome Alberta Blue Cross as the first major provincial insurer to cover Psychedelic-Assisted Therapy in all of its forms,” said Philippe Lucas, PhD, President of SABI Mind, a psychedelic clinic group based in Alberta.
  • In fall 2022, Alberta became the first province to regulate psychedelic-assisted therapy for mental health treatments, and in a recent FAQ to healthcare providers, the Alberta Blue Cross explained that claims for psychedelic therapy in Alberta are eligible for reimbursement under plan members’ drug and psychology benefits.
  • We call on other insurers, both in the public and private sector to follow the example set by Alberta Blue Cross.”

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, Depression, Congress, PD, Patient, OUD, CIAS, Sale, G&A, DMT, Șaeș, Pivotal, Psilocybin, Atai, TRD, Investment, Ibogaine, Pharmacokinetics, Safety, PTSD, OTF, Pharmaceutical industry

“In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.

Key Points: 
  • “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc., streamlining clinical, general and administrative operations.
  • atai realized operational efficiencies by simplifying and optimizing its organizational structure in line with its revised business and pipeline priorities.
  • In August 2023, the Phase 1 study results demonstrated that 9 mg/kg of oral ibogaine leads to robust psychedelic experiences.

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Patient, Chairperson, CNS, Mental health, Innovation, CMPS, Psilocybin, TRD, Johnson & Johnson, Operation, Pain, KCL, Frustration, J&J, Food, Nursing

David Norton, lead independent director on the Compass board of directors, will become interim chair.

Key Points: 
  • David Norton, lead independent director on the Compass board of directors, will become interim chair.
  • Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.
  • “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways.
  • He has been a member of the Compass board of directors since 2018, serving as lead independent director.

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Retrieved on: 
Tuesday, March 26, 2024
The Company, Disease, Research, News, Nature, Health Canada, Psilocybin, OTC, Safety, Transaction, Food

Psyence has built a network of potential clients and customers, and successfully and lawfully distributed psilocybin internationally, both itself and via its strategic partners.

Key Points: 
  • Psyence has built a network of potential clients and customers, and successfully and lawfully distributed psilocybin internationally, both itself and via its strategic partners.
  • Psyence will play a vital role in ensuring the commercial success of the Transaction target non-clinical assets and business and will continue exploring new markets for medical grade psilocybin and active pharmaceutical ingredients.
  • Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively the "Company") are forward-looking statements and are prospective in nature.
  • If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Tuesday, April 9, 2024
Psilocybin, Alzheimer's disease, Partnership, Research, Parkinson's disease, Inflammatory bowel disease, Therapy, Intellectual property, Bryostatin, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

HYTN Secures GMP Certification

Retrieved on: 
Thursday, March 21, 2024
Certification, Growth, Therapeutic Goods Administration, Good manufacturing practice, Psilocybin, GMP, Cannabis, TGA, Drug

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN "HYTN or The Company"), a Canadian company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, has been awarded Good Manufacturing Practice (GMP) certification by Australia's Therapeutic Goods Administration (TGA) for its Kelowna production facility.

Key Points: 
  • VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN "HYTN or The Company"), a Canadian company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, has been awarded Good Manufacturing Practice (GMP) certification by Australia's Therapeutic Goods Administration (TGA) for its Kelowna production facility.
  • Effective March 15th, 2024, this certification enables HYTN to manufacture cannabis dried flower into bulk and finished GMP medical products.
  • Although the company has previously serviced limited export opportunities, compliance with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products through this new GMP certification now enables HYTN to engage in broader international trade.
  • It also coincides with the emergence of a brand new and sizable market in Germany, also requiring GMP certification for medicinal cannabis products.

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
Thursday, March 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

Retrieved on: 
Monday, March 18, 2024
Psilocybin, Depression, Patient, Research, MDXX, Sale, BHC, Ahmad Adaya, Prescription, GMP, Clinical trial, OTC, Authorization, MDMA, Special access program, Pharmaceutical industry

Ltd. (Cortexa), in what is an Australian and the Company believes a world first, has supplied GMP Psilocybin for therapeutic use outside of a clinical trial to a patient under the authorised prescriber scheme.

Key Points: 
  • Ltd. (Cortexa), in what is an Australian and the Company believes a world first, has supplied GMP Psilocybin for therapeutic use outside of a clinical trial to a patient under the authorised prescriber scheme.
  • The patient was being treated with Psilocybin for treatment resistant depression.
  • In doing so, Cortexa is now established as the only Australian company able to immediately supply and deliver both GMP MDMA and Psilocybin for both clinical trials and prescriptions via the TGA’s Authorised Prescriber Scheme.
  • Cortexa has created a national network of relationships with research institutes, key opinion leaders and emerging clinicians, and supported psychiatrists for obtaining their authorised prescriber status.

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Retrieved on: 
Tuesday, March 12, 2024
Psilocybin, Hospice, Letter, Growth, Newcourt, Psychotherapy, Mental health, Research, Fungus, Contract research organization, Adjustment disorder, NCE, Phase, Optimism, Intellectual property, Patent, Therapy, Medicine, PBM, Pharmaceutical industry

Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.

Key Points: 
  • Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.
  • While other companies are exploring synthetic psilocybin, Psyence is the world’s first Nasdaq traded biopharmaceutical company researching a nature-derived (non-synthetic) psilocybin candidate.
  • Furthermore, Psyence is the only publicly traded company to research a non-synthetic psilocybin candidate to treat Adjustment Disorder in the context of Palliative Care.
  • To reflect this exciting new chapter in our company’s evolution, we have created a new investor presentation, which can be found here .

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Retrieved on: 
Tuesday, March 12, 2024
Mental Health, Health, Health Technology, Other Health, Pharmaceutical, Biotechnology, Psilocybin, Depression, Patent, Anxiety, Investment, Drug development, Addiction, Therapy, Collection, Pharmaceutical industry

11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and is further expected to issue, on March 19, 2024, U.S. Patent No.

Key Points: 
  • 11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and is further expected to issue, on March 19, 2024, U.S. Patent No.
  • The newly issued patent and soon to be issued patent provide composition of matter claim coverage on numerous potential drug candidates not previously publicly disclosed by Enveric, as well as to six compounds subject to the three recently announced Non-Binding Term Sheets that Enveric entered into with an undisclosed biotechnology company.
  • “The new patent and soon-to-issue patent expand our patent portfolio and strengthen the opportunity presented to our current and future partners and licensees.
  • They also highlight the breadth of the available patent coverage for other molecules available for licensing in the Company’s PsybraryTM collections of licensable portfolios,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.